

Specific Reveal AST system designated a breakthrough device

Aug. 24, 2022—[BioMérieux](#) announced that its Specific Reveal rapid antimicrobial susceptibility test system has received breakthrough device designation from the FDA.

The test system provides phenotypic antibiotic susceptibility test results directly from a positive blood culture in about 5.5 hours.

BioMérieux acquired Specific Diagnostics, which developed the test, in May.